Table 3.

Factors associated with hospitalisation in children and young people with COVID-19 (N=606)

	Univariable OR (95% CIs)	Multivariable OR* (95% CIs)
Female (vs male)	1.2 (0.6 to 3.8)	1.1 (0.6 to 2.4)
Age (years)	1.0 (0.9 to 1.1)	1.0 (0.9 to 1.0)
Rheumatic disease
JIA	(comparator)	(comparator)
SLE/MCTD, Vasculitis	3.8 (1.8 to 8.1)†	4.3 (1.7 to 11)†
Auto-inflammatory syndromes	2.0 (0.8 to 4.9)	3.0 (1.1 to 8.6)†
Other	1.3 (0.4 to 4.1)	1.7 (0.5 to 5.5)
Obesity	3.1 (1.2 to 8.0)†	4.0 (1.3 to 12)†
Glucocorticoid use	2.7 (1.3 to 5.9)†	2.1 (0.8 to 5.6)
DMARD use
None stated	(comparator)	(comparator)
csDMARD only	0.9 (0.4 to 2.1)	0.6 (0.2 to 1.7)
b/tsDMARD only	0.9 (0.4 to 2.1)	1.5 (0.6 to 3.6)
Combination therapy	0.5 (0.2 to 1.3)	0.4 (0.1 to 1.5)

*Adjusted for disease activity (remission, low, moderate to high, or unknown) and dataset (EULAR COVID-19 Registry or CARRA (CARRA Registry and CARRA COVID-19 GPRD)).

†P<0.05.

b/tsDMARD, biologic or targeted-synthetic DMARD; CARRA, Childhood Arthritis and Rheumatology Research Alliance; csDMARD, conventional-synthetic DMARD; DMARD, disease modifying anti-rheumatic drug; EULAR, European Alliance of Associations for Rheumatology; GPRD, Global Paediatric Rheumatology Database; JIA, juvenile idiopathic arthritis; MCTD, mixed-connective tissue disease; SLE, systemic lupus erythematosus.